Sotorasib for Lung Cancers with KRAS p.G12C Mutation

Anneloes Noordhof (Leeuwarden, Netherlands), Wouter H. van Geffen (Leeuwarden, Netherlands)

Source: Journal Club 2022
Number: 2

Webcast

Rating: 0
You must login to grade this presentation.

Share or cite this content

Citations should be made in the following way:
Anneloes Noordhof (Leeuwarden, Netherlands), Wouter H. van Geffen (Leeuwarden, Netherlands). Sotorasib for Lung Cancers with KRAS p.G12C Mutation. Journal Club 2022

You must login to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.

Member's Comments

No comment yet.
You must Login to comment this presentation.


Related content which might interest you:
Clinical characteristics of 32 patients with BRAF V600E-mutated lung adenocarcinoma
Source: International Congress 2015 – Advances in the therapy of lung cancer
Year: 2015


LSC - 2017 - KRAS & TP53 mutations cause malignant mesothelioma
Source: International Congress 2017 – Pleural disease and mesothelioma: from the bench to the bedside
Year: 2017

EGFR, KRAS, HER2, BRAF and PI3KCA mutation status in metastatic cancer patients: Thoracic cytological specimens obtained in routine clinical practice
Source: Annual Congress 2013 –Progress in bronchoscopy and pathology techniques for diagnosis of thoracic malignancies
Year: 2013


KRAS & TP53 mutations cause malignant mesothelioma
Source: ERS Lung Science Conference 2017
Year: 2017

Equal efficacy of gefitinib in chemonaive lung adenocarcinoma patients with either exon 19 deletion or L858R point mutation
Source: International Congress 2016 – Lung cancer: therapeutic modalities, re-staging, and follow-up
Year: 2016


The prognostic value of KRAS mutation according to the gene's
Source: International Congress 2014 – Pathology and prognostic factors of thoracic tumours
Year: 2014

Cytological samples for the study of EGFR, KRAS and ALK mutations in non-small cell lung cancer
Source: Annual Congress 2013 –Progress in bronchoscopy and pathology techniques for diagnosis of thoracic malignancies
Year: 2013


Mapping of KRAS mutations during chemical carcinogenesis
Source: Virtual Congress 2020 – Inflammatory pathways in chronic airway diseases
Year: 2020


NRAS mutations destine tumor cells to the lungs
Source: International Congress 2015 – New frontiers in biomedical research on thoracic tumours
Year: 2015

Frequency and type of EGFR mutations in patients with adenocarcinoma of the lung
Source: Annual Congress 2013 –Prognostic factors and subtyping of lung cancer
Year: 2013


Gene expression of EGFR, MINA53,MEN1 and MTOR in NSCLCs
Source: International Congress 2014 – Biology and pathology of thoracic tumours
Year: 2014


Lung adenocarcinoma with concomitant EGFR mutation and ALK rearrangement: Analysis of two cases and literature review
Source: International Congress 2016 – Basic science and case reports in lung cancer
Year: 2016


LATE-BREAKING ABSTRACT: Treatment efficacy of afatinib vs gefitinib in lung adenocarcinoma with EGFR gene mutation
Source: International Congress 2016 – Prognostic variables in lung cancer II
Year: 2016


Prognostic value of EGFR mutation in NSCLC in surgical stage
Source: International Congress 2014 – Biology and pathology of thoracic tumours
Year: 2014

Are KRAS mutations druggable?
Source: New biomarkers, molecules and therapeutic sequences for non small cell lung carcinoma in the era of precision medicine
Year: 2019



Homozygous deletion of PTEN and poor outcomes in EGFR mutant NSCLC patients with gefitinib therapy
Source: International Congress 2015 – Lung cancer therapy: clinical trials
Year: 2015

Germ-line exon 21 EGFR mutations, V843I and P848L, in nonsmall cell lung cancer patients
Source: Eur Respir Rev 2014; 23: 390-392
Year: 2014


A detailed immunohistochemical analysis of PI3K/AKT/MTOR pathway in lung cancer: Correlation with PIK3CA, AKT1, K-RAS or PTEN mutational status and clinicopathological features
Source: Annual Congress 2013 –Prognostic factors and subtyping of lung cancer
Year: 2013

Novel two mechanisms for acquired EGFR-TKI resistance in lung cancer cells harboring EGFR activating mutation
Source: International Congress 2014 – Pathology and prognostic factors of thoracic tumours
Year: 2014

Gefitinib as first-line treatment for patients with NSCLC with activating EGFR mutationin exons 19 (Del19) or 21 (L858R) in the Czech Republic
Source: International Congress 2015 – Lung cancer therapy: clinical trials
Year: 2015